140 related articles for article (PubMed ID: 9391546)
1. The heterogeneity of leukemia occurring after treatment for sarcoma.
Varterasian M; Zalupski M; Karanes C
Am J Clin Oncol; 1997 Dec; 20(6):585-6. PubMed ID: 9391546
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
Quintás-Cardama A; Daver N; Kim H; Dinardo C; Jabbour E; Kadia T; Borthakur G; Pierce S; Shan J; Cardenas-Turanzas M; Cortes J; Ravandi F; Wierda W; Estrov Z; Faderl S; Wei Y; Kantarjian H; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):401-10. PubMed ID: 24875590
[TBL] [Abstract][Full Text] [Related]
3. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
Kaplan HG; Malmgren JA; Atwood MK
BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
[TBL] [Abstract][Full Text] [Related]
4. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndrome and acute leukaemia following treatment of soft tissue sarcoma.
de Graeff A; Vendrik CP; Pinedo HM
Neth J Med; 1989 Jun; 34(5-6):251-7. PubMed ID: 2671758
[TBL] [Abstract][Full Text] [Related]
6. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
Gale RP; Hlatky L; Sachs RK; Radivoyevitch T
Leuk Res; 2014 Oct; 38(10):1162-4. PubMed ID: 25175829
[No Abstract] [Full Text] [Related]
7. Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease.
Hoppe RT
Leukemia; 1992 Nov; 6 Suppl 4():155-7. PubMed ID: 1434819
[No Abstract] [Full Text] [Related]
8. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma.
Travis LB; Weeks J; Curtis RE; Chaffey JT; Stovall M; Banks PM; Boice JD
J Clin Oncol; 1996 Feb; 14(2):565-71. PubMed ID: 8636772
[TBL] [Abstract][Full Text] [Related]
9. Second malignancies following treatment in non-Hodgkin's lymphoma.
Ellis M; Lishner M
Leuk Lymphoma; 1993 Mar; 9(4-5):337-42. PubMed ID: 8348069
[TBL] [Abstract][Full Text] [Related]
10. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
Kaplan H; Malmgren J; De Roos AJ
Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
[TBL] [Abstract][Full Text] [Related]
11. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report.
Ishikawa M; Nakayama K; Rahman MT; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Nakayama N; Miyazaki K
Eur J Gynaecol Oncol; 2014; 35(4):443-8. PubMed ID: 25118489
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
[TBL] [Abstract][Full Text] [Related]
13. Incidence and susceptibility to therapy-related myeloid neoplasms.
Leone G; Fianchi L; Pagano L; Voso MT
Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
[TBL] [Abstract][Full Text] [Related]
14. Risk of leukemia following treatment for non-Hodgkin's lymphoma.
Travis LB; Curtis RE; Stovall M; Holowaty EJ; van Leeuwen FE; Glimelius B; Lynch CF; Hagenbeek A; Li CY; Banks PM
J Natl Cancer Inst; 1994 Oct; 86(19):1450-7. PubMed ID: 8089863
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related myelodysplasia and acute myeloid leukemia.
Bhatia S
Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to therapy-related myelodysplastic syndromes and acute myeloid leukemia.
Sill H
Clin Adv Hematol Oncol; 2008 Mar; 6(3):164-5. PubMed ID: 18391913
[No Abstract] [Full Text] [Related]
17. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia.
Longmore G; Guinan EC; Weinstein HJ; Gelber RD; Rappeport JM; Antin JH
J Clin Oncol; 1990 Oct; 8(10):1707-14. PubMed ID: 2213106
[TBL] [Abstract][Full Text] [Related]
18. [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].
Haase D; Hanf V; Schulz T
Med Klin (Munich); 2004 Sep; 99(9):506-17. PubMed ID: 15372180
[TBL] [Abstract][Full Text] [Related]
19. Leukemia incidence following primary breast carcinoma treatment.
Kaplan HG; Malmgren JA; Atwood M
Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update.
Barnard DR; Woods WG
Leuk Lymphoma; 2005 May; 46(5):651-63. PubMed ID: 16019502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
